- Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
- Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
- Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
- Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
- Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
- Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
More ▼
Key statistics
On Thursday, Gossamer Bio Inc (GOSS:NSQ) closed at 0.6368, 40.73% above the 52 week low of 0.4525 set on Oct 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.64 |
---|---|
High | 0.6533 |
Low | 0.622 |
Bid | 0.637 |
Offer | 0.65 |
Previous close | 0.6368 |
Average volume | 1.38m |
---|---|
Shares outstanding | 226.22m |
Free float | 219.54m |
P/E (TTM) | -- |
Market cap | 144.06m USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼